Humana shares surge 15% near $446: Is the 2028 Medicare recovery already priced in?

Humana Inc. (NYSE: HUM), the Louisville, Kentucky-based health insurer and Medicare Advantage specialist, surged approximately 15% on October 9, 2026, trading around $446 after new federal quality ratings revealed a dramatic improvement in its Medicare Advantage business. The Centers for Medicare & Medicaid Services awarded four-star or higher ratings to contracts covering approximately 95% of Humana’s Medicare Advantage membership for 2027, reversing a prolonged period of ratings pressure that had weakened the company’s earnings outlook. The improvement is particularly consequential because the 2027 ratings determine Medicare Advantage quality-related payments in 2028, potentially restoring substantial revenue previously lost through weaker ratings. However, the rally has created a new valuation question: whether Humana’s future earnings can justify a share price that has already incorporated a significant recovery in expectations.

At approximately $446 per share, based on an October 9 intraday market reference rather than a confirmed closing price, Humana carried an indicative equity market capitalisation of $53.6 billion, calculated using approximately 120.08 million shares outstanding at June 30, 2026. Compared with the previous closing price of $387.12, the increase represents roughly $7.1 billion in additional equity market value in a single session. Yet Humana reaffirmed its full-year 2026 adjusted earnings guidance of at least $9 per share, substantially below the $17.14 in adjusted earnings reported for 2025. The difference between the immediate market repricing and the delayed financial benefits of improved Medicare ratings is the central issue now shaping Humana’s valuation.

Why did Humana shares surge after the 2027 Medicare Advantage Star Ratings announcement?

The October 9 announcement represented a significant turnaround in a quality-rating programme that directly influences the economics of Medicare Advantage plans. Humana reported that 18 of its Medicare Advantage contracts received ratings of at least four stars, comprising 12 four-star contracts and six 4.5-star contracts. Approximately 42% of its Medicare Advantage members were enrolled in contracts carrying 4.5-star ratings, while its member-weighted average Star Rating increased from 3.84 for Bonus Year 2027 to 4.17 for Bonus Year 2028. The company also reported that 17 contracts improved their ratings, with 11 additional contracts qualifying for four-star quality bonus payments in 2028.

The improvement extends beyond a statistical classification because Medicare Advantage insurers receive payments determined partly by quality performance, enrolment, risk adjustment and plan design. Contracts rated four stars or higher generally qualify for quality bonus payments, while higher ratings can also influence the portion of benchmark-related rebates retained for member benefits. A major improvement across contracts with substantial enrolment can therefore alter the financial resources available to an insurer over the following payment cycle. For Humana, whose earlier ratings deterioration had contributed to significant earnings pressure, the latest results materially improve the visibility of its 2028 recovery.

The clinical and operational developments behind the recovery provide additional context. Humana reported that its quality improvement programmes helped close approximately 663,000 additional gaps in care on a membership-adjusted basis compared with the preceding year. The company also reported 534,000 additional members completing annual preventive visits, reflecting more intensive engagement around screenings and preventive healthcare. Although these improvements do not establish that every downstream medical cost will decline, they indicate that the ratings recovery involved measurable changes in care delivery and member engagement rather than simply a favourable change in the scoring system.

The market response was also shaped by the scale of the improvement relative to expectations. Humana’s renewed position in highly rated Medicare Advantage contracts strengthens its competitive standing at a time when some other major managed-care companies experienced weaker quality-rating outcomes. Nevertheless, quality ratings are only one component of future earnings, and the additional revenue associated with a higher rating must be evaluated alongside healthcare claims, premiums, member benefits and operating expenses. The share-price rally consequently reflects a more credible recovery pathway, not completed delivery of the earnings associated with that pathway.

How much additional Medicare revenue could Humana receive in 2028?

Humana’s October 9 regulatory filing provides an important framework for understanding the potential financial benefit. Using a standardised comparison that normalises differences in geography, risk scores, membership composition and plan benefits, the company calculated approximately $160 in monthly Star Ratings-related revenue per member for Bonus Year 2028. That compared with an estimated peer-group median of approximately $105 and a top-quartile performance threshold of roughly $115 per member per month. The calculations indicate that Humana’s ratings performance is materially stronger than the benchmark it considers necessary to compete effectively over the longer term.

The difference between the company’s standardised $160 figure and the approximately $115 top-quartile threshold is $45 per member per month, equivalent to $540 over 12 months under the same illustrative assumptions. However, this is not a forecast that Humana will receive an additional $540 of unrestricted cash or profit for every enrolled member. The calculation incorporates both quality bonus payments and incremental rebate retention, while holding important variables constant to allow comparisons among insurers. Actual 2028 revenue will depend on that year’s enrolment, geographic exposure, risk scores, Medicare payment benchmarks, plan bids and rebate arrangements.

The distinction matters because even a substantial increase in quality-related revenue does not flow directly into operating profit. Medicare Advantage plans use portions of their available funding to offer additional member benefits, improve product competitiveness, compensate healthcare providers and support clinical programmes. Some of the financial benefit may be necessary merely to restore the company’s position following previous ratings deterioration, rather than representing entirely new economic value. Consequently, the market cannot reasonably capitalise the full potential increase in government payments as though it were an equivalent increase in recurring net income.

Humana has explicitly recognised this limitation in its forward-looking statements. The company intends to design its products and benefits around performance approximating its top-quartile target, rather than assuming that all of the unusually strong 2028 ratings advantage can be retained indefinitely. Management expects some of the outperformance above that benchmark to be non-recurring and anticipates using the resulting benefit for one-time investments and additional shareholder returns. The precise amount and proposed allocation have not yet been established, making the difference between a sustainable earnings recovery and a temporary financial windfall especially important.

Is Humana stock expensive at $446 compared with its current earnings?

Humana’s share-price recovery becomes more complicated when measured against reported earnings rather than anticipated Medicare bonus payments. The company generated adjusted earnings per share of $17.14 during FY2025, meaning the stock trades at approximately 26 times that historical adjusted earnings figure at $446. Using the FY2026 adjusted earnings guidance floor of $9 would produce a mechanical multiple of 49.6 times, but this is not a conventional forward price-to-earnings ratio because management has issued a minimum earnings threshold rather than a precise full-year forecast. The appropriate valuation question is therefore how quickly sustainable earnings can recover from the current period of pressure and what multiple that recovered earnings base would justify.

Humana’s first-half performance reinforces the importance of separating quarterly results from the annual earnings outlook. The company reported adjusted earnings of $7.61 per share in the second quarter and $17.91 per share for the first six months of 2026, reflecting the pronounced seasonality of its health insurance business. Medical claims expenses generally increase as the year progresses, while Medicare benefits and prescription drug spending patterns also affect the timing of profitability. Consequently, first-half earnings should not be doubled to estimate annual results, particularly when management continues to indicate substantially lower full-year earnings.

The current share price can also be examined through hypothetical future earnings rather than a single forecast. At $446, annual adjusted earnings of $25 per share would imply a price-to-earnings multiple of approximately 17.8 times, while $30 per share would imply approximately 14.9 times. Earnings of $35 per share would reduce that multiple to about 12.7 times, assuming the share price remained unchanged. These figures are valuation sensitivities rather than management projections, and they illustrate the scale of earnings recovery that could make the present valuation appear more conventional for an established health insurer.

Can Humana restore Medicare Advantage margins to at least 3% by 2028?

Improved quality ratings address an important revenue constraint, but medical cost management remains equally significant to Humana’s recovery. The company reported a second-quarter 2026 Insurance segment benefit ratio of 91.2%, compared with a full-year guidance range centred on 92.75%, with a tolerance of 25 basis points in either direction. This ratio measures benefits expense as a proportion of premium revenue, making it one of the most important indicators of underwriting profitability. A rising benefit ratio means a larger proportion of premiums is being absorbed by healthcare claims, leaving less revenue available to cover administration, financing and profit.

Humana has outlined a goal of returning its individual Medicare Advantage business to a sustainable pretax margin of at least 3% by 2028. The objective depends on more than additional Star Ratings revenue because medical utilisation, reimbursement rates, pharmacy spending and the profitability of newly enrolled members also influence the result. Management expects its 2027 plan bids to contribute meaningful progress toward the 2028 margin target, supported by pricing discipline, clinical programmes and operating efficiencies. However, the target remains a management objective rather than an achieved operating result, and there is no assurance that future medical costs or government payment policies will develop as anticipated.

Medical cost inflation presents a substantial uncertainty because Humana’s financial exposure extends across millions of beneficiaries. The company has indicated that combined medical and pharmacy cost trends remain elevated, with the composition of healthcare spending influenced by hospital utilisation, prescription drug expenses and the health characteristics of its membership. Even relatively small changes in benefit ratios can materially affect profitability when applied across the company’s large Medicare premium base. An improvement in Star Ratings revenue could consequently be offset by higher medical costs if pricing and benefit design fail to respond effectively.

Will Humana’s expanding Medicare membership and CenterWell business strengthen earnings?

Humana’s operating scale has increased significantly during the current year, providing another potential foundation for the 2028 recovery. Individual Medicare Advantage membership reached approximately 6.45 million at June 30, 2026, compared with 5.23 million a year earlier, representing growth of approximately 23.4%. Management has maintained an expectation for individual Medicare Advantage membership to increase by approximately 25% during 2026, supported by new enrolment and improved retention. This expansion increases the potential earnings contribution from successful pricing and operational improvements, but it also creates greater exposure to medical costs and the characteristics of newly acquired members.

The economics of membership growth depend on the profitability of the additional enrolment rather than the headline increase alone. Newly enrolled members may require additional care coordination, onboarding expenses and investments in clinical engagement before reaching the profitability levels associated with established members. Humana has also acknowledged that newer Medicare Advantage members, on average, have contributed to a higher benefit ratio than retained members after excluding the separate Star Ratings revenue effect. That means growth in membership can support future earnings while simultaneously placing pressure on near-term underwriting margins.

The company’s CenterWell healthcare services business provides an additional opportunity to improve the economics of care delivery. During the first half of 2026, CenterWell Senior Primary Care recorded growth of approximately 130,900 patients, representing an increase of 27%, as Humana expanded its healthcare delivery capabilities. The business combines primary care, pharmacy and other healthcare services that can support closer patient engagement and more coordinated management of chronic conditions. Nevertheless, the financial benefits depend on execution, contractual arrangements and actual clinical outcomes, rather than the assumption that expanding healthcare service operations automatically reduces insurance claims.

Why will the 2027 Medicare Star Ratings affect payments in 2028 rather than immediately?

The timing of the Medicare Advantage quality programme is essential to understanding the stock’s immediate valuation. The Centers for Medicare & Medicaid Services published the 2027 Star Ratings on October 8, 2026, ahead of the annual Medicare open enrolment period running from October 15 through December 7. These ratings help beneficiaries compare plans available for 2027 coverage, but the associated quality bonus calculations influence Medicare Advantage payments in 2028. The ratings announced in October therefore improve visibility into a future payment period rather than establishing an immediate increase in Humana’s 2026 earnings.

The financial benefit will also depend on the membership and contractual circumstances that exist when the relevant payments are calculated. Medicare Advantage reimbursement incorporates geographic benchmarks, member risk scores, plan bids and rebate formulas, while the amount ultimately available to support earnings depends on benefit design and healthcare costs. Humana’s current ratings advantage is significant, but the company has cautioned that actual Star Ratings revenue per member in 2028 will differ from the standardised comparison disclosed in its regulatory filing. Treating the full theoretical payment benefit as certain recurring profit would therefore overstate the degree of earnings visibility.

The distinction becomes particularly important when considering the sustainability of the recovery beyond 2028. Humana has indicated confidence in achieving top-quartile results for Bonus Year 2029, but management does not expect all the exceptional outperformance associated with 2028 to repeat. Changes in the Star Ratings programme, movement of members between contracts and other structural factors may alter the relative advantage available in subsequent payment periods. A durable valuation premium would consequently require evidence that Humana can maintain competitive quality performance and earnings margins without depending indefinitely on an unusually favourable single-year ratings outcome.

What earnings scenarios could justify or challenge Humana’s current share price?

A constructive scenario would involve Humana maintaining top-quartile Medicare Advantage quality performance while steadily restoring its individual Medicare Advantage pretax margin toward the company’s target of at least 3%. Growth in membership would provide a larger operating base, while more disciplined benefit design and claims management would improve the profitability of that base. CenterWell could contribute additional earnings through expansion and more effective integration with the insurance business, supported by productivity improvements and operating cost controls. If those developments produced sustainable adjusted earnings materially above the current guidance floor, the valuation near $446 would become easier to support.

A more moderate recovery could still produce stronger earnings without fully validating the most optimistic expectations reflected in the rally. Humana might regain a significant portion of its lost quality-related revenue while using much of the benefit to maintain attractive health plans, compensate providers and strengthen its competitive position. Higher membership could increase absolute operating profit even if margins recovered more slowly than management intends. Under those conditions, the company could emerge financially stronger in 2028 while still facing questions about whether its share-price recovery had moved ahead of fundamentals.

A less favourable scenario would involve continuing medical cost inflation, weaker Medicare payment conditions or more expensive member benefits absorbing much of the ratings-related revenue improvement. Humana could also face difficulties sustaining the exceptionally strong quality performance achieved for 2027, especially as programme methodologies and competitive conditions evolve. If adjusted earnings remained substantially below historical levels after 2028, the current valuation would become increasingly dependent on further recovery expectations rather than demonstrated profitability. That would leave the shares vulnerable to downward earnings revisions despite the genuine improvement in the company’s quality ratings.

The most useful distinction is between a one-time financial benefit and a recurring change in earnings capacity. Additional revenue used for temporary investments or shareholder distributions may create economic value, but it cannot automatically be capitalised at the same multiple as an enduring annual profit stream. Conversely, an improvement that permanently strengthens underwriting margins or reduces operating costs could justify a more lasting valuation reassessment. The extent to which Humana converts the ratings recovery into recurring profitability will therefore determine whether the current market repricing is sustainable.

What should Humana’s November earnings and December investor update reveal?

Humana’s next scheduled financial catalyst is its third-quarter earnings announcement on November 6, 2026, when updated medical cost trends, membership developments and operating performance should provide additional evidence about the current recovery trajectory. The company has already reaffirmed its minimum adjusted earnings outlook for 2026, but the third-quarter results could clarify the remaining-year earnings profile and any changes in underwriting assumptions. The Insurance segment benefit ratio will be particularly important because it reveals whether the company is managing claims expenses in line with expectations. Developments in CenterWell, Medicaid operations and membership retention will provide further context for the longer-term earnings outlook.

The December 10 investor update could be even more consequential for interpreting the stock’s valuation. Management plans to assess progress against the earnings recovery framework established at its 2025 Investor Day, including the initiatives supporting profitability through 2028. More detailed information about the durability of top-quartile Star Ratings performance, the path toward the Medicare Advantage margin target and the allocation of potential 2028 financial benefits would strengthen the investment analysis. However, Humana has indicated that a fuller assessment of the unusual 2028 ratings outperformance may not be available until more information emerges about future payment rates, membership composition and competitive conditions.

The latest ratings announcement has materially improved Humana’s operating outlook, but it has also raised the financial expectations embedded in its share price. At approximately $446, the stock is no longer valued as though the company’s Medicare Advantage challenges will necessarily persist without meaningful improvement, while its current earnings guidance still reflects substantial pressure. The more defensible interpretation is that the market has assigned considerable value to a recovery that is now more credible but remains dependent on medical costs, margins, member economics and the treatment of potentially non-recurring revenue. Humana’s next financial disclosures must demonstrate that the October ratings success can become sustainable earnings growth rather than simply a large future increase in government-related revenue.

Disclaimer: This article is for informational and journalistic purposes only and does not constitute investment advice, a recommendation, an offer or a solicitation to buy or sell any security. Investors should conduct their own research and consider their financial circumstances, objectives and risk tolerance before making investment decisions.